- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Acitretin combined with itraconazole is effective against Onychomycosis
In a study led by Mohamed Nasr it was shown that Acitretin has the potential to be a potent therapeutic agent in the treatment of onychomycosis, with higher efficacy when combined with itraconazole. The findings of this study were published in Mycoses Journal.
Onychomycosis is a fungal infection of the nail that causes subungual hyperkeratosis, discoloration, and onycholysis. Dermatophytes, yeasts (Candida), and non-dermatophyte moulds are among the pathogens involved. It is a difficult therapeutic challenge. The total cure rate with itraconazole pulse therapy remains unsatisfactory, indicating the need for a more effective treatment regimen. Given the success of itraconazole and isotretinoin in the treatment of recurrent dermatophytosis, the therapeutic use of acitretin in onychomycosis was investigated in this study, it also assessed and compared the efficacy of combined itraconazole and acitretin therapy versus monotherapy with each in the treatment of onychomycosis.
This study included 135 adult patients with onychomycosis of the finger and/or toe nails. They were divided into three groups based on their effectiveness: itraconazole pulse therapy, acitretin, and combined itraconazole/acitretin therapy. The drugs were given for three months. The severity of onychomycosis was determined using the onychomycosis severity index score. At the beginning and end of the study, potassium hydroxide microscopy and culture were performed.
The results of this study stated as follow:
1. Onychomycosis was completely cured in 51.1% and 20% of the itraconazole groups, 28.9% and 28.9% of the acitretin groups, and 80% and 53.3% of the combined group, respectively.
2. The combined itraconazole/acitretin therapy had a statistically significant advantage over the other groups (P.05).
The major limitations of this study were the very few sample size and a short duration of the project.
In conclusion, this study found that combining acitretin and pulsed itraconazole is superior to pulsed itraconazole alone in onychomycosis treatment.
references:
Nasr M, Abd-Elhamid N, Abd-Allah D, Elkholy B. Acitretin: Could it be a new therapeutic player in the field of onychomycosis? Mycoses. 2022 Feb 1. doi:10.1111/myc.13424. Epub ahead of print. PMID: 35103343.
Keywords: dermatophytosis, Mycoses, Onychomycosis, fungal infection, Acitretin, itraconazole, antifungals, hyperkeratosis,
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751